Objective: In this study, we aimed to retrospectively investigate the frequency of healthcare-associated infections, infection sites, culture proven microorganisms and antibiotic resistance properties registered in the surveillance system, in our Pediatric Intensive Care Unit over the past five years. Material and Methods: The data of healthcare-associated infections detected in patients in our 12-bed pediatric intensive care unit, which are all third-level, were collected from January 1, 2012 to December 31, 2016 retrospectively. Infection rate and density were made. Culture proven microorganisms and antibiotic resistance properties were recorded. Results: The data of 2545 patients who were followed in the pediatric intensive care unit during the study period were collected. Mortality rate was 9%. The total number of in patient days was 20.696. The median age of the patients was 3 years (min: 2 months, max: 18 years). The total number of patients with health care-associated infection was 60, the infection rate was 2.36 and infection density was 2.89. Laboratoryproven bloodstream infection was detected in 15 patients and the rate of infection was 0.59 and the density was 0.72. In seven patients, central venous catheter-related bloodstream infection was observed and the rate of infection was 0.27 and the density was 0.33. In nine patients, catheter-related urinary tract infection was detected and the rate of infection was 0.35 and the density was 0.43. Ventilator-associated pneumonia was observed in 30 patients and the rate of infection was 1.18 and the density was 1.44. Isolated microorganisms were as follows: Pseudomonas aeruginosa in 17 cases, Acinetobacter baumannii in 14 cases, Klebsiella pneumoniae in 9 cases, Serratia marcescens in 5 cases, Escherichia coli in 4 cases, Candida albicans in 4 cases, coagulase negative ©Telif Hakkı 2017 Çocuk Enfeksiyon Hastalıkları Derneği-Makale metnine www.cocukenfeksiyon.org web sayfasından ulaşılabilir.
Presentación de casos clínicos RESUMEN La anafilaxia es una reacción de hipersensibilidad sistémica y grave, de inicio rápido y potencialmente mortal. En los recién nacidos prematuros, el sistema inmunitario aún no ha madurado y, por lo tanto, tienen menos probabilidades de presentar anafilaxia. La administración de amikacina, que contenía metabisulfito de sodio, a un prematuro de 3 días de vida le indujo anafilaxia casi mortal. Debido a que se sospechaba un caso de anafilaxia, se inició la administración de amikacina en el bebé. Una vez comenzado el tratamiento, se observó una mejoría clínica. Al tercer día de tratamiento con amikacina, el recién nacido tuvo, repentinamente, taquipnea, taquicardia, angioedema y cianosis. Se le diagnosticó anafilaxia y se inició el tratamiento. Una hora después de la mejoría clínica, se produjo una reacción tardía. Inmediatamente, se intubó al recién nacido. La anafilaxia es una emergencia médica; por lo tanto, los médicos deben realizar una evaluación rápida y atenta para detectar esta reacción potencialmente mortal. Incluso después del tratamiento satisfactorio de la anafilaxia, el paciente debe permanecer bajo observación durante 72 horas dada la posibilidad de una reacción bifásica.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.